Yonsei University
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Private
- Established
- 1885-01-01
- Employees
- 5K
- Market Cap
- -
- Website
- http://www.yonsei.ac.kr
Precision Treatment With Angiotensin Converting Enzyme Inhibitor
Phase 4
Completed
- Conditions
- Hypertension
- Interventions
- Drug: genotyping and selection of renin-angiotensin system blocker
- First Posted Date
- 2022-09-10
- Last Posted Date
- 2023-01-11
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 77
- Registration Number
- NCT05535595
- Locations
- 🇰🇷
Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of
Comparison of the Electric Plasma Surgical Tool "PlasmaBlade" for Replacement of the Deep Brain Stimulation (DBS) Devices With Conventional Surgery
Recruiting
- Conditions
- Essential TremorEpilepsyParkinson DiseaseDystonia
- First Posted Date
- 2022-09-10
- Last Posted Date
- 2022-09-10
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 50
- Registration Number
- NCT05535556
- Locations
- 🇰🇷
Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of
Phase Ib/II Study to Evaluate the Safety and Efficacy of Nivolumab in Combination With Paclitaxel in Epstein-Barr Virus(EBV)-Related, or Microsatellite Instability-High (MSI-H), or Programmed Cell Death Ligand 1 (PD-L1) Positive Advanced Gastric Cancer
Phase 1
Completed
- Conditions
- Recurrent/Metastatic Gastric Cancer
- Interventions
- Drug: Nivolumab, Paclitaxel
- First Posted Date
- 2022-09-10
- Last Posted Date
- 2022-09-10
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 50
- Registration Number
- NCT05535569
- Locations
- 🇰🇷
Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of
Fibroblast Growth Factor (FGFs) / Fibroblast Growth Factor Receptor (FGFRs) Genetic as a Second-line Therapy for Recurrent / Progressive Gastric Cancer With INCB054828 and Paclitaxel a Study to Evaluate the Safety and Efficacy of Combination Therapy.
Phase 1
Completed
- Conditions
- Fibroblast Growth Factors (FGFs)/Fibroblast Growth Factor Receptors (FGFRs) Genetic Aberration Gastric Cancer, INCB054828, Paclitaxel
- Interventions
- Drug: INCB054828, Paclitaxel
- First Posted Date
- 2022-09-07
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 15
- Registration Number
- NCT05529667
- Locations
- 🇰🇷
Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of
Gemcitabine With Oxaliplatin (GEMOX) in Patients With Advanced Hepatocellular Carcinoma After Failure of Sorafenib Treatment
Phase 2
Completed
- Conditions
- Hepatocellular Carcinoma, Unresectable, Advanced
- Interventions
- First Posted Date
- 2022-08-26
- Last Posted Date
- 2022-08-26
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 32
- Registration Number
- NCT05517239
- Locations
- 🇰🇷
Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of
Efficacy of Triplet Combination With Pembrolizumab, Neratinib, and Paclitaxel as a Second Line Treatment in Recurrent/Advanced Gastric Cancer Having Somatic Human Epidermal Growth Factor Receptor Family (EGFR, HER2, HER3, HER4) Mutations or HER2 Amplification/Overexpression
Phase 2
Withdrawn
- Conditions
- Recurrent/Advanced Gastric Cancer
- Interventions
- Drug: Chemotherapy
- First Posted Date
- 2022-08-23
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- Yonsei University
- Registration Number
- NCT05512182
- Locations
- 🇰🇷
Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of
Pembrolizumab and Trifluridine/Tipiracil With Previously Treated Advanced Gastric Cancer
Phase 1
Active, not recruiting
- Conditions
- Gastric and Gastroesophageal Junction Adenocarcinoma
- Interventions
- First Posted Date
- 2022-08-19
- Last Posted Date
- 2024-12-31
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 75
- Registration Number
- NCT05508737
- Locations
- 🇰🇷
Severance Hospital, Seoul, Korea, Republic of
Detection of Tumor DNA Through Cervical Smear and Liquid Biopsy in Endometrial Cancer Patients and Evaluation of Prognostic and Predictive Values of Tumor DNA Assay
- Conditions
- Endometrial Cancer
- First Posted Date
- 2022-08-17
- Last Posted Date
- 2022-08-17
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 300
- Registration Number
- NCT05504161
- Locations
- 🇰🇷
Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of
Detection of Circulating Tumor DNA Through Liquid Biopsies in Ovarian Cancer Patients and Evaluation of Prognostic and Predictive Values of Circulating Tumor DNA Assay.
Completed
- Conditions
- Ovarian Cancer
- First Posted Date
- 2022-08-17
- Last Posted Date
- 2022-08-26
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 300
- Registration Number
- NCT05504174
- Locations
- 🇰🇷
Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of
Nutriomics and Artificial Intelligence Nutrition Obesity Cohort
Recruiting
- Conditions
- Obesity
- First Posted Date
- 2022-08-09
- Last Posted Date
- 2022-08-09
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 650
- Registration Number
- NCT05494138
- Locations
- 🇰🇷
Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of
© Copyright 2025. All Rights Reserved by MedPath